Axa S.A. Takes $2.25 Million Position in Sotera Health (NASDAQ:SHC)

Axa S.A. acquired a new stake in Sotera Health (NASDAQ:SHC) during the 2nd quarter, Holdings Channel.com reports. The firm acquired 189,285 shares of the company’s stock, valued at approximately $2,247,000.

Several other hedge funds have also recently bought and sold shares of SHC. Principal Financial Group Inc. grew its position in Sotera Health by 27.6% in the 1st quarter. Principal Financial Group Inc. now owns 468,500 shares of the company’s stock valued at $5,627,000 after acquiring an additional 101,430 shares in the last quarter. Findell Capital Management LLC purchased a new position in shares of Sotera Health in the fourth quarter valued at approximately $8,425,000. P2 Capital Partners LLC grew its holdings in shares of Sotera Health by 27.0% in the fourth quarter. P2 Capital Partners LLC now owns 2,350,000 shares of the company’s stock valued at $39,598,000 after purchasing an additional 500,000 shares in the last quarter. William Blair Investment Management LLC increased its stake in Sotera Health by 0.6% during the 2nd quarter. William Blair Investment Management LLC now owns 1,131,455 shares of the company’s stock worth $13,430,000 after buying an additional 6,707 shares during the period. Finally, Tyro Capital Management LLC acquired a new stake in Sotera Health during the 4th quarter worth approximately $15,761,000. Institutional investors and hedge funds own 91.03% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Barclays boosted their price target on shares of Sotera Health from $14.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 6th. Royal Bank of Canada restated an “outperform” rating and set a $17.00 price target on shares of Sotera Health in a report on Tuesday, August 6th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $15.70.

Insider Activity at Sotera Health

In other Sotera Health news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the company’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $15.03, for a total value of $150,300,000.00. Following the completion of the transaction, the director now owns 49,215,301 shares in the company, valued at $739,705,974.03. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 55.12% of the company’s stock.

Sotera Health Trading Down 0.4 %

NASDAQ:SHC opened at $16.70 on Tuesday. Sotera Health has a 1 year low of $10.71 and a 1 year high of $17.44. The stock has a market cap of $4.73 billion, a P/E ratio of 87.89 and a beta of 2.07. The company has a debt-to-equity ratio of 5.46, a quick ratio of 2.59 and a current ratio of 2.93. The stock has a 50-day simple moving average of $15.32 and a 200-day simple moving average of $12.95.

Sotera Health (NASDAQ:SHC) last announced its quarterly earnings results on Monday, August 5th. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.04. Sotera Health had a return on equity of 47.26% and a net margin of 3.65%. The firm had revenue of $277.00 million during the quarter, compared to the consensus estimate of $266.45 million. During the same period in the prior year, the company posted $0.19 earnings per share. The firm’s quarterly revenue was up 8.6% compared to the same quarter last year. As a group, analysts anticipate that Sotera Health will post 0.64 earnings per share for the current fiscal year.

Sotera Health Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.